Cord stem cells for primary biliary cholangitis
Part of Digestive system clinical trials.
This trial tests whether stem cells from umbilical cord blood can help people with primary biliary cholangitis (PBC) that hasn't improved with the standard medicine (UDCA). It's a phase 1/2 study, so it's looking at safety and whether it might work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 75 years.
- Diagnosed with PBC, with abnormal liver blood tests (high ALP/GGT) and/or positive specific antibodies.
- Must have tried UDCA for at least 6 months without enough improvement (ALP still high).
- Must not have other liver diseases or severe cirrhosis complications.
- Must be willing to use effective contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether slowly reducing UDCA (a medication for primary biliary cholangitis) is safe and still helpful in people whose liver tests have improved. It may help some patients avoid higher doses if their disease is well controlled.
This trial studies whether fenofibrate (a cholesterol medicine) can improve outcomes in people with primary biliary cholangitis (PBC) who already take ursodeoxycholic acid (UDCA) but still have abnormal liver blood tests. It specifically looks at people with “compensated” (stable) cirrhosis—meaning the liver disease is present but not causing severe complications right now.
This trial tests an experimental drug (CS0159) for people with primary biliary cholangitis (PBC) who either didn't respond well to or couldn't take the standard treatment UDCA. It aims to improve liver function and reduce symptoms.
This research study tracks how well Primary Biliary Cholangitis (PBC) responds to standard medication (UDCA) and what happens to patients' health over time. It may help doctors understand which treatments work best for different people.
This trial tests whether adding fenofibrate to ursodeoxycholic acid (UDCA) can improve liver test results in people with primary biliary cholangitis (PBC) who did not respond enough to UDCA alone. It aims to see if the combination works better and is safe for adults with persistent, abnormal liver markers.
This trial tracks how well the combination of ursodiol and seladelpar works in people with primary biliary cholangitis (PBC), a liver disease. It aims to see if this treatment helps control symptoms and liver function.
Hear when a new Primary Biliary Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.